The Top 10 bestselling orphan drugs in the USA in 2017. Celgene's Revlimid (generic name lenolidamide) leads the way with sales of USD 5.4 billion,…

The top 10 companies in the world ranked by global orphan drug sales and market share in 2017. Swiss giants Novartis and Roche take the top two…

In the run-up to Rare Disease Day 2019, David H. Crean, PhD, Managing Director for Objective Capital Partners, reviews the investment and deal…

It has been announced by China's State Council that as of March 1st 2019, the government will reduce the VAT on a "first batch" of 21 rare disease…

Founded in 1998, GW Pharmaceuticals is a British biopharmaceutical company, best known for being the only company with a license to cultivate cannabis…

80 orphan drugs (those drugs intended to treat diseases so rare that sponsors are reluctant to develop them under usual marketing conditions) were…

Anay Shukla leads the pharmaceutical, life sciences, med-tech and healthcare practice at Nishith Desai Associates, a leading Indian law firm. In this…

125 medicines for rare diseases were approved by the EMA between 2004 and 2014, of which 71 were granted orphan drug status. This chart shows the…

Abidin Gulmus, founder and chairman of Gen Ilaç, describes the company’s impressive journey to become Turkey’s principle orphan drug distributor…

Korean Pharma company, Hanmi has won orphan drug status this week from the US Food and Drug Administration (FDA) for HM43239, a drug for the treatment…

Patient groups oftentimes serve as the authority on a specific disease when it comes to advancing research. “Without patient perspective,…

Mirosław Zieliński, president of the Polish National Forum for the Therapy of rare diseases (ORPHAN), the representative voice for 35 Polish rare…